BamSEC and AlphaSense Join Forces
Learn More

Ovid Therapeutics Inc. – Material Contracts

NASDAQ: OVID    
Share price (4/8/26): $2.60    
Market cap (4/8/26): $343 million
Search in Documents
Key Exhibits
External Links

Material Contracts Filter

EX-10.14
from 10-K 16 pages Material contract
12/34/56
EX-10.13
from 10-K 17 pages Material contract
12/34/56
EX-10.2
from 8-K 23 pages Material contract
12/34/56
EX-10.1
from 8-K 52 pages Material contract
12/34/56
EX-10.2
from 8-K 22 pages Registration Rights Agreement
12/34/56
EX-10.1
from 8-K 63 pages Securities Purchase Agreement
12/34/56
EX-10.15
from 10-K 3 pages Material contract
12/34/56
EX-10.14
from 10-K 3 pages Material contract
12/34/56
EX-10.4
from 10-K 11 pages Material contract
12/34/56
EX-10.1
from 10-Q 16 pages Material contract
12/34/56
EX-10.1
from 8-K 15 pages Amended and Restated Executive Employment Agreement
12/34/56
EX-10.1
from 10-Q 11 pages Material contract
12/34/56
EX-10.21
from 10-K 53 pages Material contract
12/34/56
EX-10.13
from 10-K 3 pages Material contract
12/34/56
EX-10.1
from 10-Q Pdf Courtesy Copy
12/34/56
EX-10.1
from 10-Q 3 pages Ovid Therapeutics Inc. Non-Employee Director Compensation Policy
12/34/56
EX-10.1
from 8-K 56 pages License Agreement Between Astrazeneca Ab and Ovid Therapeutics Inc. Dated as of December 30, 2021
12/34/56
EX-10.1
from 10-Q 3 pages Ovid Therapeutics Inc. Non-Employee Director Compensation Policy
12/34/56
EX-10.1
from 10-Q 18 pages Amended and Restated Executive Employment Agreement
12/34/56
EX-10.1
from 10-Q 50 pages Royalty, License and Termination Agreement Relating to License and Collaboration Agreement Dated January 6, 2017 by and Between Takeda Pharmaceutical Company Limited and Ovid Therapeutics Inc. March 2, 2021
12/34/56